Investigating the pharmaceutical substances and action mechanisms of Changmaxifeng granules against tic disorders

doi:10.5498/wjp.v15.i12.112055

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 12

This Article

(39)

(70)

(0)

(689)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Psychiatry. Dec 19, 2025; 15(12): 112055
Published online Dec 19, 2025. doi: 10.5498/wjp.v15.i12.112055

Full Size Figure Download Figure

Figure 3 Characterization results of plasma components. A: Plasma total ion current diagram of negative ion mode; B: Plasma total ion current diagram of positive ion mode.

Citation: Xie LD, Wu JP, Liu SS, Zong Z, Hu Y, Ling N, Han B, Li WL, Yao HY. Investigating the pharmaceutical substances and action mechanisms of Changmaxifeng granules against tic disorders. World J Psychiatry 2025; 15(12): 112055
URL: https://www.wjgnet.com/2220-3206/full/v15/i12/112055.htm
DOI: https://dx.doi.org/10.5498/wjp.v15.i12.112055

Xie LD, Wu JP, Liu SS, Zong Z, Hu Y, Ling N, Han B, Li WL, Yao HY. Investigating the pharmaceutical substances and action mechanisms of Changmaxifeng granules against tic disorders. World J Psychiatry 2025; 15(12): 112055 [PMID: 41357924 DOI: 10.5498/wjp.v15.i12.112055]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.